611235-29-1

Basic information

• Product Name: 4-Benzyl-4,7-diazaspiro[2.5]octane
• Synonyms: 4-Benzyl-4,7-diazaspiro[2.5]octane
• CAS NO: 611235-29-1
• Molecular Formula: C₁₃H₁₈N₂
• Molecular Weight: 202.29542
• Mol File: 611235-29-1.mol

Chemical Properties

• Boiling Point: 315.4±22.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.56±0.20(Predicted)
• CAS DataBase Reference: 4-Benzyl-4,7-diazaspiro[2.5]octane(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzyl-4,7-diazaspiro[2.5]octane(611235-29-1)
• EPA Substance Registry System: 4-Benzyl-4,7-diazaspiro[2.5]octane(611235-29-1)

Safety Data

• Hazardous Substances Data: 611235-29-1(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 1261358-79-5 tert-butyl 4-benzyl-4,7-diazaspiro[2.5]octane-7-carboxylate 
• 78551-60-7 1-benzyl-4-(tert-butyloxycarbonyl)piperazin-2-one 

Downstream Products

• 1261358-78-4 4-(4-benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF

The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use - alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS

The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.